quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:35:18·39d
ANALYSTRating
BeOne Medicines Ltd. logo

BeOne Medicines downgraded by Jefferies with a new price target

ONC· BeOne Medicines Ltd.
Health Care
Original source

Companies

  • ONC
    BeOne Medicines Ltd.
    Health Care

Recent analyst ratings

  • Mar 27UpdateWolfe Research$340.00
  • Mar 16UpdateJefferies$290.00
  • Nov 24UpdateTruist-
  • Sep 18UpdateBarclays$385.00
  • Apr 7UpdateRBC Capital Mkts$312.00
  • Mar 3UpdateBofA Securities$320.00

Related

  • PR2d
    BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6
  • SEC7d
    Amendment: SEC Form SCHEDULE 13D/A filed by BeOne Medicines Ltd.
  • SEC7d
    SEC Form PRE 14A filed by BeOne Medicines Ltd.
  • SEC9d
    BeOne Medicines Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition
  • INSIDER13d
    SEC Form 4 filed by Lee Chan Henry
  • ANALYST28d
    Wolfe Research initiated coverage on BeOne Medicines with a new price target
  • INSIDER41d
    SVP, General Counsel Lee Chan Henry sold $102,300 worth of American Depositary Shares (341 units at $300.00) and exercised 341 units of American Depositary Shares at a strike of $191.64 (SEC Form 4)
  • INSIDER44d
    Chief Executive Officer Oyler John was granted 444,912 units of Ordinary Shares, increasing direct ownership by 9% to 5,609,275 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022